Corporate Overview
LINC Pharmaceutical’s technology meets a significant medical and
business need though the discovery of a natural fibrosis modulating
pathway. This discovery provides the basis of the Company's
diagnostic technology and therapeutic approaches which represent a
potent new system to combat fibrotic disease. When applied to
pulmonary disease, LINC’s breakthrough technology will provide lung
care specialists with a new effective paradigm for the treatment
progressive fibrotic lung disorders.
LINC represents an opportunity that is ideally situated at the confluence
of important technology developments and market trends. LINC's
proprietary technology has been proven in the laboratory and is now
ready for commercial development. The project thesis is sound, risks are
understood and manageable, and our operational plans robust, providing
an opportunity to create significant value for our investors while bettering
the prospects for millions threatened with intractable lung disease.
We believe that LINC is addressing the right targets with the right
technology and the right people at the right time.
[Mike Delmage and Ken Narducy]
|
